| Not Yet Recruiting | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Mitochondrial Diseases | Phase 2 | 2026-06-09 |
| Recruiting | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation PIDs Linked to PI3K | Phase 2 | 2025-04-29 |
| Active Not Recruiting | Leniolisib for Immune Dysregulation in CVID Common Variable Immunodeficiency (CVID) | Phase 2 | 2025-02-12 |
| Active Not Recruiting | Leniolisib for Immune Dysregulation in PIDs Primary Immunodeficiency Disorders (PIDs) | Phase 2 | 2024-10-21 |
| Active Not Recruiting | Pediatric Patients Aged 1 to 6 Years With APDS APDS | Phase 3 | 2023-08-30 |
| Unknown | An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS APDS Gene Mutation | Phase 3 | 2023-08-03 |
| Active Not Recruiting | Pediatric Patients Aged 4 to 11 Years With APDS APDS | Phase 3 | 2023-02-01 |
| Terminated | Prevention of Acute Kidney Injury in Patients With NSTEMI Non-ST Elevation Myocardial Infarction (NSTEMI) | Phase 2 | 2021-04-21 |
| Completed | Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Confirmed Coronavirus Disease | Phase 2 | 2020-11-30 |
| Completed | Patient Registry to Evaluate the Real-world Safety of Ruconest® Hereditary Angioedema | — | 2018-06-30 |
| Terminated | Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | 2016-09-08 |
| Completed | A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor Hereditary Angioedema | Phase 2 | 2014-12-01 |
| Completed | Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients Hereditary Angioedema | Phase 2 | 2012-01-17 |
| Completed | C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks Hereditary Angioedema | — | 2011-07-01 |
| Completed | Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Att Hereditary Angioedema | Phase 3 | 2011-01-01 |
| Withdrawn | Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation Graft Rejection, Kidney Transplantation | Phase 2 | 2010-12-01 |
| Completed | A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration Genetic Disorders, Hereditary Angioedema | Phase 2 | 2009-06-01 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Hereditary Angioedema, Angioneurotic Edema | Phase 2 / Phase 3 | 2005-07-01 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders | Phase 3 | 2004-06-01 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Genetic Disorders | Phase 2 / Phase 3 | 2004-04-01 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Genetic Disorders | Phase 2 | 2003-06-01 |